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Upregulation of p53 protein induces either growth
arrest or apoptosis in response to cellular injury This
is signaled from a highly conserved p53 domain
between codons 64 and 92, where a functional poly-
morphism results in either a proline (p53-72P) or an
arginine (p53-72R) at codon 72. Preliminary studies
suggest that p53-72R may be a risk factor for cer-
vical cancer and, consistent with this, preferential
mutation and retention of the p53-72R allele has also
been demonstrated in other cancers of squamous cell
origin. Here we examine the relationship between
allelic forms of p53 and nonmelanoma skin cancer,
by determining the correlation with susceptibility to
sunburn, which is a known risk factor, and then by
p53 sequence analysis of a large series of tumors. We
found a signi®cant positive association between p53-
72R and susceptibility to sunburn, as assessed by skin
phototype and minimal erythemal dose following
solar-simulated radiation (p = 0.0001 for trend). We
also found a signi®cant association between p53-72R
homozygosity and nonmelanoma skin cancer in
renal transplant recipients (basal cell carcinoma,
p < 0.01; squamous cell carcinoma, p < 0.05) but
not in immunocompetent patients compared with
skin type matched controls. p53 sequence data
revealed mutations in 30 of 70 (42.9%) nonmela-
noma skin cancers, 28 (93%) of which were in the
p53-72R allele. Loss of heterozygosity occurred more
frequently in p53-72RP than in p53-72RR tumors
(p = 0.0001) with preferential loss of p53-72P in het-
erozygotes (p = 0.016), irrespective of the mutant
status of the concomitant allele. Together these data
infer functional differences between polymorphic
forms of p53 that are likely to be relevant to
skin carcinogenesis. Key words: human papillomavirus/
immunosuppression/nonmelanoma skin cancer/renal trans-
plantation/ultraviolet radiation. J Invest Dermatol 119:84±
90, 2002
T
he p53 tumor suppressor protein plays a crucial part in
maintaining cellular integrity and tissue homeostasis
through its ability to orchestrate the transcriptional
activation of other genes (May, 1999). These protein±
protein complexes activate downstream p53 target
genes such as p21/Waf-1, resulting in either G1 arrest or apoptosis,
both of which play important parts in preventing tumorigenesis.
p53 belongs to a recently recognized family of homologous
proteins that includes p73 (encoded by TP73) and p63 (also known
as Ket, p40, p73L, and p51; encoded by TP63) (Kaelin, 1999). A
critical region of p53 for signaling apoptosis lies between codons 64
and 92, encoding a proline-rich region of the gene homologous to
a SH3 binding domain (Walker and Levine, 1996; Sakamuro et al,
1997; Venot et al, 1998; Zhu et al, 1999) in which there is a
common polymorphism resulting in either an arginine (CGC) or a
proline (CCC) at codon 72 of exon 4. This is a nonconservative
amino acid change and results in a structural change in the protein
as the p53Pro variant migrates more slowly than the p53Arg variant
in sodium dodecyl sulfate±polyacrylamide gel electrophoresis
(Matlashewski et al, 1987). Whereas the existence of this
polymorphism has been known since wild-type p53 complemen-
tary DNA were ®rst cloned (Lamb and Crawford, 1986), its clinical
and functional signi®cance in such a critical domain has remained
largely unexplored until very recently.
It is now known that the arginine (p53-72R) and proline
(p53-72P) polymorphic alleles have distinct biochemical and
functional properties, including their ability to signal apoptosis
following DNA damage, with its attendant potential for in¯uencing
cancer risk (Thomas et al, 1999). The two allelic forms also differ in
their relative susceptibility to human papillomavirus (HPV)-medi-
ated E6 degradation, with implications for in¯uencing the risk of
HPV 16/18-associated anogenital cancers in particular (Storey et al,
1998). Several groups have now shown a possible association
between p53-72R and susceptibility to HPV-associated cervical
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cancer, suggesting that the increased susceptibility of the p53-72R
allele to E6-mediated degradation may be clinically important
(Storey et al, 1998; Zehbe et al, 1999; Agorastos et al, 2000; van
Duin et al, 2000); however the risk of cervical cancer attributable to
p53-72R remains controversial, with other groups failing to ®nd
any obvious association (Helland et al, 1998; Hildesheim et al, 1998;
Josefsson et al, 1998; Lanham et al, 1998; Minagichi et al, 1998;
Rosenthal, 1998; Bertorelle, 1999; Klaes et al, 1999). To what
extent this re¯ects differences in ethnicity, HPV exposure, and
interlab variation in p53 genotyping remains to be established
(Makni et al, 2000).
More recently, it has also been shown that the p53-72R allele
may act as an intragenic modi®er of mutant p53 behavior (Marin et
al, 2000). Certain conformational p53 mutants can bind to and
inactivate the p73 protein, with loss of p73-induced apoptosis, a
property that is enhanced by the presence of arginine at codon 72.
The subsequent demonstration of preferential mutation and
retention of the p53-72R allele in some human cancers, including
head and neck, vulval, and a small series of skin cancers (Marin et al,
2000), and in esophageal squamous cell carcinoma (Kawaguchi et al,
2000) indicates that this interaction may be clinically relevant, at
least in squamous cell epithelia.
In this study we have evaluated the relationship between the p53
codon 72 polymorphism and skin cancer in more detail. First, we
have examined the association of the polymorphism with suscep-
tibility to sunburn [a known risk factor for nonmelanoma skin
cancer (NMSC)] and with the presence of skin cancer independent
of skin type. Secondly, a subset of tumors were investigated for
evidence of an in¯uence of the polymorphism on HPV DNA
infection, p53 mutational frequency, and/or loss of heterozygosity
(LOH). These studies were undertaken in both immunocompetent
individuals and high-risk immunosuppressed organ transplant
recipients, a population who represent an accelerated model of
skin carcinogenesis (McGregor and Proby, 1996).
MATERIALS AND METHODS
Sources and selection of the cases, controls, and healthy
volunteers Cases were selected consecutively from among patients
attending either dedicated dermatology clinics for organ transplant
recipients or general dermatology clinics at two centers in London (Barts
and the London NHS Trust and St Thomas' Hospital). Skin type
matched controls were also recruited from these two centers and
consisted of: individuals attending general dermatology or medical clinics
for problems unrelated to skin cancer; renal transplant recipients
attending dedicated dermatology clinics for screening (but who had been
transplanted for at least 10 y and had not developed skin cancer); and
healthy volunteers working in the laboratories of both hospitals. Few of
the individuals approached refused to participate (< 10 individuals across
all groups), such that this was unlikely to have in¯uenced the ®nal
composition of the groups. Volunteers for minimal erythemal dose
(MED) measurements were selected randomly from each of the skin
phototype groups.
Skin typing and MED assessment Skin type was assessed in NMSC
patients and healthy volunteers by a detailed questionnaire using the
Fitzpatrick skin typing system (Fitzpatrick, 1988), which ranges from skin
type I/II (burns easily and tans with dif®culty), III/IV (burns
occasionally, tans readily) through to skin type V (Asian) and IV (black).
The minimal dose of solar-simulated radiation (SSR) required to induce
a just perceptible erythema at 24 h (MEDjp) was determined for 77
healthy volunteers on previously unexposed buttock skin, by geometric
exposure series at six sites using Ö2 incremental doses (Diffey and Farr,
1989). SSR was generated by a 1 kW xenon arc solar simulator (Oriel,
Stratford, CT). The doses cited represent the full SSR spectrum,
including visible radiation, as determined by a wide-band thermopile
radiometer (Medical Physics, Dryburn Hospital, Durham, U.K.).
Spectroradiometric analysis (Bentham Instruments, Reading, U.K.)
showed that the ultraviolet (UV) radiation (» 295±400 nm) component
represents 45% of the total SSR dose.
Tissue samples and nucleic acid extraction Basal cell carcinoma and
squamous cell carcinoma were excised using local anesthetic following
informed consent. A radial section that included both normal and
lesional skin was taken from each specimen, snap frozen at harvest, and
stored in liquid nitrogen prior to nucleic acid isolation. The remainder
was ®xed in formol saline and stained with hematoxylin and eosin for
histopathologic diagnosis and con®rmation of excision margins. Genomic
DNA was isolated by proteinase K digestion and RNA using RNAzol B
according to the manufacturer's instructions (Biogenesis Ltd, Poole,
U.K.). Whole blood for germline genotyping was venesected from
controls and NMSC patients, and DNA extracted using a Nucleon DNA
extraction kit (Scotlab, Nucleon Biosciences, Coatbridge, Lanarkshire,
U.K.).
Polymerase chain reaction ampli®cation of germline polymorphic
sequences p53-codon 72 proline sequences were detected by
polymerase chain reaction using the primer pair p53Pro+/p53± (p53Pro+:
5¢GCCAGAGGCTGCTCCCCC; p53±: 5¢CGTGCAAGTCACAGA-
CTT), and p53-codon 72 arginine by the primer pair p53+/Arg± (p53+:
5¢TCCCCCTTGCCGTCCCAA; p53Arg±: 5¢CTGGTGCAGGGG-
CCACGC) as previously described (Storey et al, 1998).
LOH and p53 sequence analysis Samples for LOH assessment were
chosen randomly from among those tumors for which frozen tissue had
been collected at the time of surgery over a period of 10 y. LOH at 17p
was performed using three microsatellite markers D17S520, TP53, and
D17S513 (Jones and Nakamura, 1992). To identify mutation-containing
exons in p53, single strand conformation polymorphism (SSCP) analysis
was performed as previously described (Oliphant et al, 1991).
For analysis of p53 sequence, RNA was subjected to reverse transcrip-
tion using the Stratagene ®rst-strand cDNA synthesis kit (Stratagene,
Europe). Total cellular RNA was extracted from frozen cancer biopsies
with a commercially supplied phenol/guanidinium reagent according to
the manufacturer's instructions (RNAzolB; Biogenesis Ltd). RNA was
treated with DNAse (Genehunter Corporation), then used for ®rst strand
cDNA synthesis using the Prostar system (Stratagene). The p53 coding
sequence was then ampli®ed from cDNA as a 1.3 kb fragment using Pfx
DNA polymerase (Life Technologies Ltd, Paisley, UK) and cloned using
the Zero-Blunt system (Invitrogen Ltd, Paisley, UK). Mutations in p53
were identi®ed by sequencing multiple clones in the proposed region of
p53 suggested by abnormal SSCP mobility. In cancers where insuf®cient
tissue was available to allow RNA isolation, a 2.8 kb genomic DNA
fragment containing exons 4±9 of p53 were ampli®ed from genomic
DNA with Pfx DNA polymerase (Life Technologies) using primers as
previously described (Nigro et al, 1989) and again cloned with the Zero-
Blunt system. Mutations were then identi®ed by sequencing of multiple
plasmid clones. To identify in individual cancers the genotype at codon
72 in mRNA with either wild-type or mutant p53, plasmid clones were
identi®ed that contained either the mutation or were wild type. The
same plasmid clones were then sequenced in both directions through
codon 72 using additional sequencing primers.
HPV DNA detection HPV DNA was sought in a subset of 24
samples by a degenerate and nested polymerase chain reaction-based
method with a panel of oligonucleotide primers located within the
highly conserved L1 open reading frame of the HPV genome, as
previously described (Harwood et al, 1999).
Statistical analysis Comparisons between speci®ed groups were
performed using a Pearson's chi-square test or Fisher's exact test for small
numbers of observations. Genotype/skin type correlation was analyzed
using a chi-squared test for trend in proportions. MED/skin type and
MED/genotype correlation was assessed by Wilcoxon rank sum test.
Preferential loss of p53-72P in RP heterozygotes was tested using an
exact binomial test. All analyses were carried out using S-plus.
RESULTS
Characteristics of the cases, controls, and healthy
volunteers Skin cancer cases and controls were adults aged
between 18 and 75 y, matched for skin types I±III and derived
from a north-west European white population. Within the
extended healthy volunteer control population, skin types I±IV
(all of whom were of north-west European origin) and those of
skin types V and VI were included (comprising individuals of
oriental/Asian and African/Afro-Caribbean origin, respectively).
As the numbers of individuals with type V and VI skin was small, it
was not possible to stratify for each ethnic group individually,
although in future studies this would be desirable.
Patients in the two skin cancer populations (transplant and
immunocompetent groups) were deemed broadly representative of
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the skin cancer population in general as they were recruited
consecutively; however, it is possible that among the transplant
population, those with multiple cancers might be over-represented
as they were reviewed more frequently. There were no obvious
selective factors that we are aware of that might have in¯uenced
recruitment of the control populations, or in selection of samples
for LOH assessment.
Relationship between p53-72R, skin type, and MED
(Tables I and II) In our control population p53 genotypes
were in Hardy±Weinberg equilibrium for all skin phototypes
except V. There was strong correlation between skin phototype
and susceptibility to sunburn as assessed by SSR MED in 77
individuals, skin types I/II having signi®cantly lower MED than
skin types III/IV (p < 0.0001) and similarly types III/IV and V/VI
(p < 0.0001). We also found an association between p53-72R and
susceptibility to sunburn, as determined both by skin type and
MED phototesting. Among 227 volunteers, the proportion of
individuals homozygous for p53-72R was found to be 61% in skin
types I/II, decreasing sequentially to 7% in those of skin type VI
(p = 0.0001 for trend) (Table I). Median MED scores similarly
re¯ected this trend, increasing from 8.0 to 9.6 and 24 J per cm2 for
genotypes RR, RP, and PP, respectively, with a signi®cant
difference in MEDjp between genotypes RR/RP and PP
(p = 0.04), although not between RR and RP.
Relationship between p53-72R and skin cancer
(Table III) To test whether homozygous p53-72R was a risk
factor for NMSC independent of skin type, the germline p53-72
polymorphism status of 182 skin cancer patients was compared with
that of 156 skin-type matched healthy volunteers. Skin cancer
patients comprised 92 renal transplant recipients, from a population
at very high risk of multiple skin cancers (McGregor and Proby,
1996), and 90 otherwise healthy patients with skin cancer. We
found that homozygous p53-72R was signi®cantly over-
represented in transplant patients with skin cancer (p = 0.01; odds
ratio 2.1, 95% con®dence interval 1.22±3.68), for both basal cell
carcinoma (p = 0.002; odds ratio 3.76 95%, con®dence interval
1.64±8.61) and squamous cell carcinomas (p = 0.03; odds ratio
2.14, 95% con®dence interval 1.14±4.01). There was no evidence
of a signi®cant association between p53-72R homozygosity and
either basal cell carcinoma or squamous cell carcinoma in
immunocompetent patients. The odds ratios and con®dence
intervals, however, overlap for renal transplant recipients and
immunocompetent patients, and it is possible that a larger series
could show an effect.
HPV status and p53 codon 72 genotype (Table IV) As an
excess of the RR genotype in transplant patients with skin cancer
might re¯ect the HPV status of the tumors, as previously proposed
for cervical cancer (Storey et al, 1998) and esophageal tumors
(Kawaguchi et al, 2000), HPV DNA was sought in a subset of
NMSC, chosen at random from both transplant and
immunocompetent patients, using a combination of degenerate
and nested polymerase chain reaction primers capable of detecting
all known HPV, including mucosal, cutaneous, and
epidermodysplasia verruciformis (EV) types (Harwood et al,
1999); however we found no signi®cant relationship between
HPV positivity and RR genotype in this series, where both HPV
typing and p53 data were available (Table III).
P53 sequence analysis and LOH studies in NMSC (Tables IV
and V) Finally, we examined the relationship between p53
polymorphism status, p53 mutation, and LOH at the p53 locus in
70 NMSC (Table IV). These comprised 25 tumors from
immunocompetent patients and 45 from renal transplant
recipients, each randomly selected without prior knowledge of
the p53 polymorphism status. A subset of these tumors have been
previously described (Marin et al, 2000; Table IV). p53 mutations
were identi®ed in 30 of 70 (43%) of all skin tumors, with no
signi®cant difference between either transplant and immuno-
competent tumors [16 of 45 (36%) vs 14 of 25 (56%); p = 0.13], or
RR and RP genotypes [22 of 56 (39%) vs eight of 14 (57%); p
= 0.24]. Twenty-eight of 30 tumors with p53 mutations (93%)
were mutant in the R allele but as the majority of these were RR
homozygotes this did not reach statistical signi®cance. Of the eight
RP tumors that had a mutation, this was in the R allele in six (75%)
cases compared with four expected (p = 0.3). Despite a lack of
power to demonstrate preferential mutation of the R allele (Marin
et al, 2000) we were able to show that LOH was signi®cantly more
prevalent in RP tumors, being present in two of 56 RR (3.6%)
compared with seven of 14 RP cases (50%; p = 0.0001). There was
also evidence for preferential loss of p53-72P in RP heterozygotes
(all seven tumors that showed LOH lost the 72P allele vs 3.5
expected; p = 0.016), which occurred both with and without
concomitant mutation in the paired allele. These data are
summarized in Table III.
Table I. Relationship between p53-72 genotype and skin phototype in 227 healthy individuals
Skin
photoypea
Total number of
healthy volunteers
P523 codon 72 polymorphism status OR for RR genotypeb
RR (%) RP (%) PP (%) OR 95% CI
I/II 69 42 (61) 26 (38) 1(1) 1 -
III/IV 69 33 (48) 32 (46) 4 (6) 1.7 0.9-3.3
V 48 16 (33) 16 (33) 16 (33) 3.1 1.5-6.7
VI 41 3 (7) 20 (49) 18 (44) 19.7 6.8-56.7
aAccording to Fitzpatrick classi®cation (see text).
bOR, odds ratio; CI, con®dence interval.
Table II. Relationship of minimal erythemal dose to skin
phototype and p53 codon-72 polymorphism in 77 healthy
individuals
Number of
individuals
Minimal erythemal dose (J per cm2)
Median Range
Skin phototypea
I/II 42 8 2.8±11.2
III/IV 28 11.2 8±16
V/VI 7 32 16±43
Genotypeb
RR 41 8 2.8±32
RP 30 9.6 4.16
PP 6 24 5.6±43
aAssessed by Fitzpatrick's classi®cation (see text).
bAssessed by solar simulated radiation (see text).
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DISCUSSION
In this study we demonstrate an association between the arginine
and proline allelic forms of p53 codon 72 and skin phototype, as
determined by both Fitzpatrick clinical scoring and objectively by
MED assessment. The p53-72R allele was signi®cantly more
prevalent in individuals with fair skin susceptible to both burn easily
in the sun and, in the longer term, skin cancer. After allowing for
skin type, we also found an association between p53-72R and
NMSC in renal transplant patients, a group at particularly high risk
of both basal and squamous cell cancers (McGregor and Proby,
1996). The association was not present in immunocompetent
individuals with skin cancer, but this was not clearly attributable to
the differing HPV status of the tumors in the two patient groups.
Finally, p53 sequence data revealed that mutations were present in
43% of all the skin tumors, the majority (93%) occurring in the
arginine allele, as previously described in other malignant squamous
epithelia (Marin et al, 2000). There was a signi®cant increase in
LOH at the p53 locus in RP compared with RR tumors, with
preferential loss of p53-72P in RP heterozygotes, irrespective of the
mutant status of the concomitant allele. Together these data infer
potentially important functional differences between polymorphic
forms of p53 at codon 72, which are likely to be relevant to skin
carcinogenesis.
The p53 codon 72 arginine/proline polymorphism has been
recognized for almost 15 y (Lamb and Crawford, 1986).
Population-based studies indicate that the proline allelic form is
most prevalent in black-skinned races and least prevalent in those
with white skin, with a clear and consistent decline in the
prevalence of the proline allele with increasing latitude (SjaÈlander et
al, 1995). Evidence suggests that the polymorphism is balanced and
maintained at different levels in humans across the world popu-
lation, which, in a functional domain of p53 that is otherwise so
highly conserved, even through different species (Soussi et al,
1987), suggests clinically important differences between arginine
and proline at codon 72 on which natural selection pressures are
acting (Beckman et al, 1994). Studies of human fetal tissue indicate
that these are not likely to be occurring prenatally (Beckman et al,
1994), so it remains to be determined what these might be.
P53 codon 72 genotype, skin type, and erythemal
response One hypothesis is that the association between p53-
72R frequency and increasing latitude has evolved as an adaptation
to UV radiation exposure (Beckman et al, 1994). This is clearly
speculative but our data would at least be consistent with this.
There was an association of p53-72R with both fair skin type and
burn easily in the sun as measured by SSR cutaneous erythemal
response and, conversely, the p53-72P allele was most prevalent in
dark-skinned races originating from areas with high ambient UV
levels. It was not possible in this study to dissociate skin type from
ethnic background. Whether p53-72P is actually protective against
acute UV-induced DNA damage remains to be established but
certainly it was associated in our study with higher median MED
than the p53-72R genotype. In addition, in skin tumor material we
found evidence for preferential loss of p53-72P, suggesting that this
may be a necessary step in skin carcinogenesis, again implying a
possible protective effect of p53-72P. Skin cancer is an unlikely
endpoint for selection pressures to act on, however, as tumors
predominantly occur after reproductive age. Another possibility is
that the polymorphism may be linked to susceptibility to UV-
induced immunosuppression; this is also skin type related (Kelly et
al, 2000) and could in¯uence susceptibility to infection, exerting
potentially more important selective pressures. Whatever the basis
of selection, there appear to be pressures to maintain p53-72P in
black-skinned populations, and for the emergence of the p53-72R
allele in those resident in successively more temperate climates.
P53 codon 72 status and skin cancer susceptibility As p53-
72R is associated with skin types that are susceptible to burn easily
in the sun, it might also be independently associated with the
Table III. Germline frequencies of codon 72 p53 polymorphic forms in 182 skin cancer patients and 156 skin type-
matched healthy controls
Study group NMSC status
p53 codon 72 polymorphism status
(number of individuals [%])
OR for RR genotype
RR PP RP OR 95% CI
1. Controlsa 85 (55) 5 (3) 66 (42) 1 ±
2. RTRs BCC 36d (82)d 0 (0) 8 (18)d 3.76 1.64±8.61
SCC 46b (72)c 0 (0) 18 (28) 2.14 1.14±4.01
NMSC (total) 66 (72)d 0 (0) 26 (28)c 2.12 1.22±3.68
3. ICPs BCC 30 (67) 0 (0) 15 (33) 1.67 0.83±3.35
SCC 28 (62) 0 (0) 17 (38) 1.38 0.70±2.72
NMSC (total) 58 (64) 0 (0) 32 (36) 1.51 0.89±2.58
aControls comprised 18 renal transplant recipients (RTRs) and 138 immunocompetent patients (ICPs) with RR genotype frequencies of 0.56 and 0.54 respectively.
bSixteen patients had both BCC and SCC.
cDenotes signi®cance at p < 0.05.
dp<0.01 between cases and controls.
Table IV. Loss of heterozygosity (LOH) analysis, p53 mutation analysis, HPV genotyping and p53 codon 72 allelotyping
data for 25 NMSC from immunocompetent patients (ICP) and 45 NMSC from renal transplant recipients (RTR)
NMSC (ICP)
Total
(n = 25)[%]
NMSC (RTR)
Total
(n = 45)[%]
NMSC (All)
Total
(n = 70) [%]
RR
(n = 15)[%]
RP
(n = 10)[%]
RR
(n = 41)[%]
RP
(n = 4)[%]
RR
(n = 56)[%]
RP
(n = 14)[%]
LOH present 1 [6.7] 6 [60] 7[28] 1[2.3] 1 [25] 2 [4.4] 2[3.6] 7 [50] 9 [12.9]
p53 mutation 7 [47] 7 [70] 14 [56] 15 [37] 1 [25] 16 [36] 22 [39] 8 [57] 30 [43]
HPV positive 1/7 [14] 3/4 [75] 4/11 [36] 6/11 [55] 2/2 [100] 8/13 [62] 7/18 [39] 5/6 [83] 12/24 [50]
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Table V. Details of p53 codon 72 status, p53 mutational status, p53 LOH and HPV positivity in 25 NMSC from
immunocompetent patients (ICP) and 45 NMSC from renal transplant recipients (RTR)
Immune
status
Patient
type
NMSC
72 status p53 codon
LOH (allele
lost)
P53 mutation
status
Mutant
allele
HPV
status
ICP 1 SCCa RP Y(P) 236 TAC>AAC (Tyr>Asn) R ND
1 SCCa RP Y(P) 287 GAG>AAG (Glu>Lys) R ND
2 SCCa RR N Wild type ND
3 SCC RR N Wild type ND
4 SCCa RP Y(P) Wild type ND
5 SCCa RR N 224 GAG>TAG (Glu>Ter) R ND
6 BCC RP N 178 CAC>TAC (His>Tyr) P ND
7 BCC RR N 137 GCC>GAC (Ala>Asp) R ND
8 SCC RP N Wild type Neg
9 SCCa RR N 248 CGG>TGG (Arg>Trp) R Neg
10 SCCa RR Y(R) Wild type Neg
11 SCCa RR N Wild type ND
12 SCCa RP Y(P) 248 CGG>TGG (Arp>Trp) R +
13 SCCa RP Y(P) 161 GCC>GTC (Ala>Val) R ND
14 BCC RP N 138 GCC>GAC (Ala>Asp) P ND
15 BCC RR N Wild type ND
16 BCC RR N 216 GTG>GGG (Val>Gly) R Neg
17 SCCa RR N 179 CAT>TAT (His>Tyr) R Neg
18 SCC RP Y(P) 173 GTG>CTG (Val>Leu) R +
19 SCC RR N Wild type Neg
10 SCC RP N Wild type +
20 BCC RR N 290 CGC>TGC (Arg>Cys) R +
21 BCC RR N Wild type Neg
22 BCC RR N 241 TCC>CCC (Ser>Pro) R ND
23 BCC RR N Wild type ND
RTR 24 SCC RR N Wild type ND
24 SCC RR N Wild type ND
24 SCC RR N Wild type ND
24 SCC RR N 170 ACG>ACA (Thr>Ala) R ND
24 SCC RR N 80 CCT>CTT (Pro>Leu) R ND
25 SCC RR N Wild type ND
26 SCC RR N 295 CCT>CTT (Pro>Leu) R ND
27 SCC RR N Wild type ND
28 SCC RR N 243 ATG>AGG (Met>Arg) R ND
29 SCC RR N Wild type ND
29 SCC RR N Wild type ND
29 SCC RR N Wild type ND
29 SCC RR N 245 GGC>GTC (Trp>Val) R ND
29 SCC RR N 248 CGG>CAG (Arg>Gln) R ND
30 SCC RP N Wild type ND
31 SCC RR N Wild type ND
32 SCC RR N Wild type ND
32 SCC RR N 135 TGC>TGA (Cys>Ter) R ND
33 SCC RR Y(R) 85 CCT>CTT (Pro>Leu) R ND
33 SCC RR N Wild type ND
34 SCC RP Y(P) Wild type ND
35 SCC RR N 104-105 CAGGGC>CAGGGGC (frameshift) R ND
36 BCC RR N 250 CCC>CTC (Pro>Leu) R ND
37 BCC RR N 117 GGG>GGGG (frameshift) R ND
38 BCC RR N Wild type ND
39 BCC RR N Wild type ND
40 SCC RR N Wild type +
41 SCC RR N Wild type +
42 SCC RR N Wild type +
43 SCC RR N 177 CCC>CTC (Pro >Leu) R Neg
44 SCC RR N Wild type Neg
45 SCC RR N Wild type +
46 SCC RR N Wild type ND
47 SCC RR N Wild type ND
48 SCC RP N Wild type +
49 SCC RP N 309 ccC>TCC (Pro>Ser) R +
50 SCC RR N Wild type ND
51 BCC RR N 219 CCC>CTC (Pro>Leu) R Neg
52 BCC RR N Wild type ND
53 BCC RR N Wild type +
54 BCC RR N 149 TCC>TTC (Ser>Phe) R +
55 BCC RR N Wild type Neg
*56 BCC RR N Wild type Neg
41 BCC RR N 175 CTG>CAG (Arg>His) R ND
57 BCC RR N Wild type ND
aTumors previously described (Marin et al, 2000).
bSamples typed with degenerate and nested primers (Hanvood et al, 1999).
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development of skin cancer, a long-term consequence of
cumulative UV exposure. To examine this, we compared the
polymorphism status of skin cancer patients, from a high-risk
immunosuppressed transplant population and an
immunocompetent population, with skin type-matched healthy
controls. We found a signi®cant association between p53-72R and
the development of both basal cell carcinoma and squamous cell
carcinoma in transplant recipients, suggesting that it might indeed
be a risk factor for skin cancer in this group. Another study found a
similar trend in a small number of renal transplant patients with skin
cancer but this did not reach statistical signi®cance (Marshall et al,
2000); however, we found no such relationship in
immunocompetent patients with skin cancer, although the trend
was in the same direction. This might re¯ect a lack of power to
detect weaker associations, particularly as there are multiple
environmental and host factors, in particular UV exposure, which
might in¯uence skin cancer risk that the current model does not
account for. Nonetheless, having identi®ed p53-72R as a possible
risk factor for skin cancer, the hypothesis needs to be tested
prospectively in a multivariate analysis of a larger series of patients.
P53 codon 72 genotype, immune status, and HPV status in
skin cancer patients If p53-72R is a risk factor for the
development of skin cancer, it is not clear why a difference
should exist between transplant and nontransplant patients since
tumors from both groups appear otherwise to behave similarly with
respect to p53 mutation prevalence and LOH at the p53 locus
(McGregor et al, 1997). It has been proposed that transplant-
associated tumors may have a different etiology, in particular that
they may be causally associated with HPV infection, which is more
prevalent in organ transplant recipients (Proby et al, 1996).
Detection of HPV DNA is signi®cantly higher in transplant than
in nontransplant tumors, and often includes multiple HPV types of
a broad phylogenetic spectrum within single lesions (Harwood et al,
2000). Although we found no overall relationship between HPV
status and genotype in the present study, it may be found to exist
for speci®c HPV types which we would not have the statistical
power to detect, in a small series of all HPV-positive skin tumors
from 29 patients were compared with 69 healthy controls, p53-
72R homozygosity was signi®cantly associated with NMSC even
in the immunocompetent population (Dokianakis et al, 2000). At a
mechanistic level, whether preferential degradation of p53-72R by
the diverse HPV types present in skin tumors could account for
susceptibility of homozygous p53-72R transplant patients to skin
cancer remains to be investigated. Similarly, p53-72R and p53-72P
alleles appear to differ in ability to signal apoptosis (Thomas et al,
1999) and a differential effect of HPV-encoded E6 proteins on their
apoptotic capacity could potentially account for the apparent excess
risk of skin cancer in homozygous p53-72RR transplant patients
and needs to be tested. The recently described ability of cutaneous
HPV types to inhibit UV-induced apoptosis in cells containing
wild-type p53 by degradation of Bak (Jackson, 2000a; Jackson,
2000b) may also be relevant in this context is also unclear.
Preferential mutation of R allele and loss of P allele p53
gene mutations were present in 30 of 70 (43%) of all skin tumors
examined, approximately equally in transplant and nontransplant
tumors, as previously reported (McGregor et al, 1997), and in RR
and RP tumors alike. The majority of all mutations occurred in the
p53-72R allele, although we were unable to show that this was
statistically signi®cant as there were so few RP tumors in the series.
Nonetheless, p53-72R was mutant in six of the eight RP
heterozygotes where a p53 mutation was present and these data
accord with previous p53 sequence data in squamous cell epithelia
from predominantly anogenital tumors where signi®cant
preferential mutation of p53-72R is demonstrable (Marin et al,
2000).
We also found that LOH was signi®cantly more common in RP
than RR tumors, with preferential loss of p53-72P, irrespective of
the mutant status of the concomitant p53-72R allele. Together
these data are consistent with the hypothesis that p53-72R is
preferentially mutated and retained in squamous cell tumors where
it confers a selective advantage for tumorigenesis by neutralizing
p73-induced apoptosis (Marin et al, 2000). Conversely, selection at
the tumor level for loss of p53-72P suggests a possible protective
effect of the proline-containing allele against skin cancer.
Potential confounding factors Our descriptive study of p53
codon 72 genotypes in skin cancer patients and healthy controls
indicates that p53-72R is associated with fair skin type and that it
may independently confer susceptibility to skin cancer in high-risk
immunosuppressed patients. Its conclusions are limited by sample
size and by possible confounders, including ethnicity, UV
exposure, gender, and HPV status of tumors. Some of these can
be addressed in future studies, employing multivariate analysis, but
ethnicity in particular is dif®cult to dissociate from skin type. For
example, we cannot exclude the possibility that our data re¯ect an
association between p53-72R and speci®c ethnic groups, rather
than skin type. The parallel decline in p53-72P alleles with
increasing latitude makes this conclusion less likely, however,
particularly as populations with similar skin types but marked ethnic
and genetic dissimilarities, e.g., Indian and African populations,
nonetheless display close similarities in codon 72 genotype
frequencies (Beckman et al, 1994).
To dissociate, as far as is possible, ethnicity from skin type, the
relationship between p53 genotype frequency and erythemal
response should be con®rmed in individuals of different skin type
within a single ethnic population. The ethnicity of individuals with
skin types I±IV in this study was of broadly similar north-west
European origin, although some degree of ethnic heterogeneity
cannot be entirely excluded. If these individuals are strati®ed within
skin type groups I±IV, the trend with respect to codon 72 status
remains, but there is insuf®cient power to show statistical
signi®cance. This is largely because individuals of skin type IV
are poorly represented in our population. Another group, however,
have recently reported just such a signi®cant association between
p53-72R genotype frequency and skin type within an apparently
homogeneous caucasian population of presumed uniform ethnicity
(Bastiaens et al, 2001).
In summary, we report a relationship between p53-72R and
susceptibility to burn easily in the sun. In addition, in high-risk
immunosuppressed groups we found that p53-72R was associated
with the development of both basal and squamous cell carcinomas,
although this relationship was not demonstrable in immunocom-
petent patients with skin cancer. In squamous cell tumors there is
evidence of preferential mutation and retention of the p53-72R
allele, together with selective loss of p53-72P. Binding of mutant
p53-72R to p73 with subsequent loss of p73-induced apoptosis
provides a plausible mechanism for the susceptibility to skin cancer
that the p53-72R genotype may confer, but other explanations may
emerge. Conversely, the demonstration that p53-72P is frequently
lost in tumors suggests a possible protective effect of this allele
against skin cancer. This would be consistent with the high
prevalence of p53-72P alleles found in dark-skinned races living
close to the equator and exposed to high levels of UV radiation.
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